LifeStance Health Gr Analyst Ratings
LifeStance Health Gr Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/13/2023 | 14.68% | Morgan Stanley | $10 → $10 | Reiterates | Overweight → Overweight |
05/19/2023 | 3.21% | Goldman Sachs | $8 → $9 | Maintains | Neutral |
05/11/2023 | 14.68% | Morgan Stanley | $8 → $10 | Maintains | Overweight |
01/06/2023 | -8.26% | Morgan Stanley | → $8 | Upgrades | Equal-Weight → Overweight |
11/15/2022 | -8.26% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
11/14/2022 | -8.26% | Cowen & Co. | $10 → $8 | Maintains | Outperform |
11/07/2022 | — | Jefferies | Assumes | → Buy | |
08/22/2022 | 14.68% | Cowen & Co. | $11 → $10 | Maintains | Outperform |
05/10/2022 | -8.26% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
03/21/2022 | 14.68% | Goldman Sachs | $15 → $10 | Maintains | Neutral |
03/17/2022 | 14.68% | UBS | $19 → $10 | Downgrades | Buy → Neutral |
12/17/2021 | 14.68% | Morgan Stanley | $15 → $10 | Maintains | Equal-Weight |
11/09/2021 | 37.61% | JP Morgan | $24 → $12 | Downgrades | Overweight → Neutral |
09/10/2021 | 106.42% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
08/16/2021 | 83.49% | Morgan Stanley | $36 → $16 | Downgrades | Overweight → Equal-Weight |
07/06/2021 | 289.91% | UBS | → $34 | Initiates Coverage On | → Buy |
07/06/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
07/06/2021 | 312.84% | Morgan Stanley | → $36 | Initiates Coverage On | → Overweight |
07/06/2021 | 312.84% | JP Morgan | → $36 | Initiates Coverage On | → Overweight |
07/06/2021 | 186.7% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變化 | 上一頁/當前額定值 |
---|---|---|---|---|---|
07/13/2023 | 14.68% | 摩根士丹利 | 10 美元 → 10 美元 | 重申 | 超重 → 超重 |
05/19/2023 | 3.21% | 高盛 | 8 美元 → 9 美元 | 維護 | 中立 |
05/11/2023 | 14.68% | 摩根士丹利 | 8 美元 → 10 美元 | 維護 | 超重 |
01/06/2023 | -8.26% | 摩根士丹利 | → 8 美元 | 升級 | 重量相等 → 超重 |
11/15/2022 | -8.26% | 高盛 | 9 美元 → 8 美元 | 維護 | 中立 |
11/14/2022 | -8.26% | Cowen & Co. | 10 美元 → 8 美元 | 維護 | 跑贏大盤 |
2022 年 7 月 11 日 | — | 傑富瑞 | 假設 | → 購買 | |
08/22/2022 | 14.68% | Cowen & Co. | 11 美元 → 10 美元 | 維護 | 跑贏大盤 |
05/10/2022 | -8.26% | 摩根士丹利 | 10 美元 → 8 美元 | 維護 | 重量相等 |
03/21/2022 | 14.68% | 高盛 | 15 美元 → 10 美元 | 維護 | 中立 |
03/17/2022 | 14.68% | 瑞銀(UBS) | 19 美元 → 10 美元 | 降級 | 買入 → 中性 |
12/17/2021 | 14.68% | 摩根士丹利 | 15 美元 → 10 美元 | 維護 | 重量相等 |
2021 年 9 月 11 日 | 37.61% | 摩根大通 | 24 美元 → 12 美元 | 降級 | 超重 → 中性 |
2021 年 10 月 9 日 | 106.42% | Cowen & Co. | → 18 美元 | 開啓覆蓋範圍 | → 跑贏大盤 |
2021 年 8 月 16 日 | 83.49% | 摩根士丹利 | 36 美元 → 16 美元 | 降級 | 超重 → 重量相等 |
2021 年 6 月 7 日 | 289.91% | 瑞銀(UBS) | → 34 美元 | 開啓覆蓋範圍 | → 購買 |
2021 年 6 月 7 日 | — | 威廉布萊爾 | 開啓覆蓋範圍 | → 跑贏大盤 | |
2021 年 6 月 7 日 | 312.84% | 摩根士丹利 | → 36 美元 | 開啓覆蓋範圍 | → 超重 |
2021 年 6 月 7 日 | 312.84% | 摩根大通 | → 36 美元 | 開啓覆蓋範圍 | → 超重 |
2021 年 6 月 7 日 | 186.7% | 高盛 | → 25 美元 | 開啓覆蓋範圍 | → 中立 |
What is the target price for LifeStance Health Gr (LFST)?
LifeStance Health Gr (LFST) 的目標價格是多少?
The latest price target for LifeStance Health Gr (NASDAQ: LFST) was reported by Morgan Stanley on July 13, 2023. The analyst firm set a price target for $10.00 expecting LFST to rise to within 12 months (a possible 14.68% upside). 8 analyst firms have reported ratings in the last year.
摩根士丹利於2023年7月13日公佈了LifeStance Health Gr(納斯達克股票代碼:LFST)的最新目標股價。這家分析公司將目標股價定爲10.00美元,預計LFST將在12個月內升至10.00美元(可能上漲14.68%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for LifeStance Health Gr (LFST)?
分析師對LifeStance Health Gr(LFST)的最新評級是多少?
The latest analyst rating for LifeStance Health Gr (NASDAQ: LFST) was provided by Morgan Stanley, and LifeStance Health Gr reiterated their overweight rating.
LifeStance Health Gr(納斯達克股票代碼:LFST)的最新分析師評級由摩根士丹利提供,LifeStance Health Gr重申了其增持評級。
When is the next analyst rating going to be posted or updated for LifeStance Health Gr (LFST)?
LifeStance Health Gr(LFST)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LifeStance Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LifeStance Health Gr was filed on July 13, 2023 so you should expect the next rating to be made available sometime around July 13, 2024.
分析師在進行了廣泛的研究,包括瀏覽公開財務報表、與LifeStance Health Gr的高管和客戶交談以及聽取財報電話會議後得出股票評級。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。LifeStance Health Gr的最後一次評級是在2023年7月13日提交的,因此你應該預計下一個評級將在2024年7月13日左右公佈。
Is the Analyst Rating LifeStance Health Gr (LFST) correct?
分析師對 LifeStance Health Gr (LFST) 的評級正確嗎?
While ratings are subjective and will change, the latest LifeStance Health Gr (LFST) rating was a reiterated with a price target of $10.00 to $10.00. The current price LifeStance Health Gr (LFST) is trading at is $8.72, which is out of the analyst's predicted range.
雖然評級是主觀的,會發生變化,但最新的LifeStance Health Gr(LFST)評級得到了重申,目標股價爲10.00美元至10.00美元。LifeStance Health Gr(LFST)目前的交易價格爲8.72美元,超出了分析師的預測區間。